NME6

Summary

NME6 (NME/NM23 nucleoside diphosphate kinase 6, HGNC:20567) is a protein-coding gene on chromosome 3p21.31, encoding Nucleoside diphosphate kinase 6, mitochondrial (O75414). Catalytic subunit of a complex with RCC1L, which catalyzes the transfer of a gamma-phosphoryl group from a nucleoside triphosphate, mainly ATP, to a nucleoside diphosphate via a ping-pong mechanism involving the formation of a phosphohistidine intermediate. It is a selective cancer dependency (DepMap: 10.7% of cell lines).

Nucleoside diphosphate (NDP) kinases (EC 2.7.4.6), such as NME6, are ubiquitous enzymes that catalyze transfer of gamma-phosphates, via a phosphohistidine intermediate, between nucleoside and dioxynucleoside tri- and diphosphates (Mehus et al., 1999 [PubMed 10453732]).

Source: NCBI Gene 10201 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 43 total
• Cancer dependency (DepMap): dependent in 10.7% of screened cell lines
• MANE Select transcript: NM_001308426

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20567
Approved symbol	NME6
Name	NME/NM23 nucleoside diphosphate kinase 6
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	NM23-H6, IPIA-ALPHA
Ensembl gene	ENSG00000172113
Ensembl biotype	protein_coding
OMIM	608294
Entrez	10201

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 30 protein_coding, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000302378, ENST00000415053, ENST00000415644, ENST00000418431, ENST00000421967, ENST00000425930, ENST00000426689, ENST00000435684, ENST00000442597, ENST00000444069, ENST00000447314, ENST00000447724, ENST00000451657, ENST00000452211, ENST00000454531, ENST00000456495, ENST00000484959, ENST00000494209, ENST00000495734, ENST00000642710, ENST00000643011, ENST00000643457, ENST00000885416, ENST00000885417, ENST00000885418, ENST00000885419, ENST00000885420, ENST00000885421, ENST00000885422, ENST00000885423, ENST00000926844, ENST00000926845, ENST00000926846, ENST00000943101, ENST00000943102, ENST00000943103

RefSeq mRNA: 9 — MANE Select: NM_001308426 NM_001308426, NM_001308427, NM_001308428, NM_001308430, NM_001308431, NM_001308433, NM_001308434, NM_001308435, NM_005793

CCDS: CCDS2763, CCDS77733, CCDS77734, CCDS82767, CCDS82768

Canonical transcript exons

ENST00000442597 — 6 exons

Exon	Start	End
ENSE00001171664	48296119	48296158
ENSE00001637596	48292317	48294803
ENSE00001766952	48301353	48301367
ENSE00003494090	48295075	48295235
ENSE00003548624	48296727	48296829
ENSE00003556954	48298427	48298523

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 88.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.5682 / max 47.4131, expressed in 1775 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42101	7.2620	1768
42102	0.3062	117

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.96	gold quality
ventricular zone	UBERON:0003053	87.50	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.64	gold quality
right uterine tube	UBERON:0001302	86.14	gold quality
monocyte	CL:0000576	85.95	gold quality
stromal cell of endometrium	CL:0002255	85.89	gold quality
granulocyte	CL:0000094	85.40	gold quality
leukocyte	CL:0000738	85.39	gold quality
rectum	UBERON:0001052	85.37	gold quality
mononuclear cell	CL:0000842	85.31	gold quality
ganglionic eminence	UBERON:0004023	85.14	gold quality
muscle of leg	UBERON:0001383	84.81	gold quality
islet of Langerhans	UBERON:0000006	84.72	gold quality
gastrocnemius	UBERON:0001388	84.59	gold quality
right ovary	UBERON:0002118	84.38	gold quality
left ovary	UBERON:0002119	84.25	gold quality
mucosa of transverse colon	UBERON:0004991	84.18	gold quality
colonic epithelium	UBERON:0000397	84.17	gold quality
body of pancreas	UBERON:0001150	84.15	gold quality
ectocervix	UBERON:0012249	84.13	gold quality
metanephros cortex	UBERON:0010533	83.95	gold quality
adrenal tissue	UBERON:0018303	83.93	gold quality
apex of heart	UBERON:0002098	83.77	gold quality
cortical plate	UBERON:0005343	83.73	gold quality
cerebellar hemisphere	UBERON:0002245	83.59	gold quality
cerebellar cortex	UBERON:0002129	83.51	gold quality
gall bladder	UBERON:0002110	83.42	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.41	gold quality
body of uterus	UBERON:0009853	83.32	gold quality
body of stomach	UBERON:0001161	83.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

96 targeting NME6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-150-5P	99.99	66.69	1976
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-370-5P	99.78	66.81	706
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-7156-5P	99.64	68.81	1369

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• It was suggested that rs1076394 served as an expression Quantitative Trait Loci (eQTL) for gene CCDC12 and NME6, while NME6’s expression was obviously higher in colorectal cancer tissues. (PMID:27120998)
• Mitochondrial NME6 Influences Basic Cellular Processes in Tumor Cells In Vitro. (PMID:39273527)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	nme6	ENSDARG00000016138
mus_musculus	Nme6	ENSMUSG00000032478
rattus_norvegicus	Nme6	ENSRNOG00000020721
drosophila_melanogaster	nmdyn-D6	FBGN0030573

Paralogs (8): NME8 (ENSG00000086288), NME3 (ENSG00000103024), NME4 (ENSG00000103202), NME5 (ENSG00000112981), NME7 (ENSG00000143156), NME9 (ENSG00000181322), NME1 (ENSG00000239672), NME2 (ENSG00000243678)

Protein

Protein identifiers

Nucleoside diphosphate kinase 6, mitochondrial — O75414 (reviewed: O75414)

Alternative names: Inhibitor of p53-induced apoptosis-alpha, nm23-H6

All UniProt accessions (9): O75414, A0A0C4DG91, A0A2R8Y547, A0A2R8Y7V2, C9J1J2, C9J867, C9J9V6, C9JQB1, F2Z2J2

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of a complex with RCC1L, which catalyzes the transfer of a gamma-phosphoryl group from a nucleoside triphosphate, mainly ATP, to a nucleoside diphosphate via a ping-pong mechanism involving the formation of a phosphohistidine intermediate. Participates in the regulation of mitochondrial nucleotide levels, mitoribosome biogenesis, and mitochondrial RNA abundances. Supplies pyrimidine ribonucleoside triphosphates (rNTPs) for mitochondrial transcription and is required for the maintenance of mitochondrial DNA (mtDNA) when the import of pyrimidine deoxyribonucleoside triphosphates (dNTPs) is limited from the cytosol is limited. As a monomer, lacks nucleoside diphosphate kinase (NDPK) activity.

Subunit / interactions. Monomer; lacks nucleoside diphosphate kinase (NDPK) activity. Interacts with RCC1L; this interaction mediates activation of nucleoside diphosphate kinase activity.

Subcellular location. Mitochondrion matrix. Mitochondrion inner membrane. Mitochondrion.

Tissue specificity. Highly expressed in the heart, placenta, skeletal muscles, kidney, prostate, ovary, intestine, and spleen. Also expressed in various cell lines and the expression levels differed among cell lines.

Similarity. Belongs to the NDK family.

Isoforms (4)

UniProt ID	Names	Canonical?
O75414-1	1	yes
O75414-2	2
O75414-3	3
O75414-4	4

RefSeq proteins (9): NP_001295355, NP_001295356, NP_001295357, NP_001295359, NP_001295360, NP_001295362, NP_001295363, NP_001295364, NP_005784 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001564	Nucleoside_diP_kinase	Family
IPR023005	Nucleoside_diP_kinase_AS	Active_site
IPR034907	NDK-like_dom	Domain
IPR036850	NDK-like_dom_sf	Homologous_superfamily
IPR037994	NDPk6	Family

Pfam: PF00334

Catalyzed reactions (Rhea), 4 shown:

• a ribonucleoside 5’-diphosphate + ATP = a ribonucleoside 5’-triphosphate + ADP (RHEA:18113)
• UDP + ATP = UTP + ADP (RHEA:25098)
• CDP + ATP = CTP + ADP (RHEA:25237)
• a 2’-deoxyribonucleoside 5’-diphosphate + ATP = a 2’-deoxyribonucleoside 5’-triphosphate + ADP (RHEA:44640)

UniProt features (15 total): binding site 6, splice variant 3, mutagenesis site 2, chain 1, domain 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75414-F1	93.86	0.90

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 129 (pros-phosphohistidine intermediate)

Ligand- & substrate-binding residues (6): 19; 68; 96; 102; 116; 126

Mutagenesis-validated functional residues (2):

Position	Phenotype
129	loss interaction with rccl1. loss of phosphorylation. loss of nucleoside diphosphate kinase activity.
129	affects mitochondrial dna level.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-499943	Interconversion of nucleotide di- and triphosphates

MSigDB gene sets: 200 (showing top): GOBP_REGULATION_OF_NUCLEAR_DIVISION, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, GOBP_GROWTH, GOBP_PYRIMIDINE_NUCLEOSIDE_TRIPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS, GOBP_ORGANELLE_FISSION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE

GO Biological Process (8): GTP biosynthetic process (GO:0006183), UTP biosynthetic process (GO:0006228), CTP biosynthetic process (GO:0006241), apoptotic process (GO:0006915), nucleotide metabolic process (GO:0009117), pyrimidine ribonucleotide salvage (GO:0010138), negative regulation of cell growth (GO:0030308), negative regulation of mitotic nuclear division (GO:0045839)

GO Molecular Function (7): nucleoside diphosphate kinase activity (GO:0004550), ATP binding (GO:0005524), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), mitochondrial matrix (GO:0005759)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of nucleotides	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
pyrimidine ribonucleotide biosynthetic process	3
pyrimidine ribonucleoside triphosphate biosynthetic process	2
purine ribonucleotide biosynthetic process	1
purine ribonucleoside triphosphate biosynthetic process	1
GTP metabolic process	1
UTP metabolic process	1
CTP metabolic process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
nucleoside phosphate metabolic process	1
pyrimidine nucleotide salvage	1
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
regulation of mitotic nuclear division	1
negative regulation of cell cycle process	1
negative regulation of mitotic cell cycle	1
negative regulation of nuclear division	1
mitotic nuclear division	1
phosphotransferase activity, phosphate group as acceptor	1
nucleobase-containing compound kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

5464 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NME6	RP2	O75695	620
NME6	NT5M	Q9NPB1	490
NME6	A0A087WWV3	A0A087WWV3	479
NME6	OSBPL11	Q9BXB4	461
NME6	NT5C1B	Q96P26	461
NME6	RABGGTB	P53611	458
NME6	POLR2E	P19388	458
NME6	TBCK	Q8TEA7	454
NME6	DTYMK	P23919	453
NME6	NIPAL2	Q9H841	439
NME6	GART	P22102	436
NME6	WDR47	O94967	435
NME6	AK9	Q5TCS8	426
NME6	NT5C1A	Q9BXI3	409
NME6	UQCRC1	P31930	404

IntAct

27 interactions, top by confidence:

A	B	Type	Score
DBF4	CDC7	psi-mi:“MI:0914”(association)	0.890
RCC1L	NME6	psi-mi:“MI:0914”(association)	0.720
RCC1L	NME6	psi-mi:“MI:0915”(physical association)	0.720
NME6	RCC1L	psi-mi:“MI:0915”(physical association)	0.720
NME6	E6	psi-mi:“MI:0915”(physical association)	0.370
NME6	ZNRD2	psi-mi:“MI:0915”(physical association)	0.370
MRPL12		psi-mi:“MI:0914”(association)	0.350
DHH	NME6	psi-mi:“MI:0914”(association)	0.350
NOCT	NME6	psi-mi:“MI:0914”(association)	0.350
TRUB2	NME6	psi-mi:“MI:0914”(association)	0.350
COQ2	NME6	psi-mi:“MI:0914”(association)	0.350
HOGA1	NME6	psi-mi:“MI:0914”(association)	0.350
UQCRFS1	VWA8	psi-mi:“MI:0914”(association)	0.350
NME6	HSPD1	psi-mi:“MI:0914”(association)	0.350
CLIC5	NME6	psi-mi:“MI:0914”(association)	0.350
FECH	GTPBP10	psi-mi:“MI:0914”(association)	0.350
PTP4A1	NME6	psi-mi:“MI:0914”(association)	0.350
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (30): NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), NME6 (Affinity Capture-MS), ATP5O (Two-hybrid), NME6 (Affinity Capture-RNA), NME6 (Proximity Label-MS), WBSCR16 (Affinity Capture-MS), BCS1L (Affinity Capture-MS), HSPD1 (Affinity Capture-MS), NME6 (Affinity Capture-MS)

ESM2 similar proteins: A2ARP1, A2VD68, A7T167, A7Z050, B3DL53, B3M1E1, B3P4N5, B4GZ20, B4HJC0, B4KA23, B4LVS8, B4NKI9, B4PVH6, B4QVW6, O00746, O35552, O54820, O60361, O75414, O88425, O88426, P0C644, P34093, P56597, P78820, P87355, Q16875, Q1JQ92, Q29B63, Q5R9C1, Q66KP0, Q6DGQ8, Q6DI51, Q6NLG3, Q6PFW1, Q715S9, Q715T0, Q7JUX9, Q8N427, Q91YL3

Diamond homologs: A0A1L1SUL6, A1V4K4, A2S299, A3M207, A3MK78, A3NA57, A3NVX4, A4F9J8, A4G4J8, A4XY36, A5F3F7, A5IC43, A5UDJ8, A5UI22, A6Q200, A6SZX4, A6V0V6, A6VMK7, A7I3D2, A7MU38, A8ERJ2, A9HJV3, A9IK55, B0RT49, B0USF1, B0V4U1, B0VKS3, B2FNQ5, B2I3E1, B2SXT3, B3E3P0, B3PDL7, B4SSW2, B5FAW8, B7H073, B7I5G3, B7UWI4, B7VJT4, B8IZ74, B9MFX2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	31
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

574 predictions. Top by Δscore:

Variant	Effect	Δscore
3:48295070:CTCA:C	donor_loss	1.0000
3:48295071:TCA:T	donor_loss	1.0000
3:48295073:A:AC	donor_gain	1.0000
3:48295073:A:T	donor_loss	1.0000
3:48295073:AC:A	donor_gain	1.0000
3:48295074:C:CA	donor_loss	1.0000
3:48295074:C:CC	donor_gain	1.0000
3:48295074:CC:C	donor_gain	1.0000
3:48295074:CCCGA:C	donor_gain	1.0000
3:48295231:GCCCG:G	acceptor_gain	1.0000
3:48295232:CCCG:C	acceptor_gain	1.0000
3:48295232:CCCGC:C	acceptor_gain	1.0000
3:48295233:CCG:C	acceptor_gain	1.0000
3:48295233:CCGC:C	acceptor_gain	1.0000
3:48295234:CG:C	acceptor_gain	1.0000
3:48295234:CGC:C	acceptor_gain	1.0000
3:48295236:C:CC	acceptor_gain	1.0000
3:48295236:CT:C	acceptor_loss	1.0000
3:48295238:G:C	acceptor_gain	1.0000
3:48295238:G:GC	acceptor_gain	1.0000
3:48295243:C:CT	acceptor_gain	1.0000
3:48295244:A:T	acceptor_gain	1.0000
3:48295068:GACTC:G	donor_loss	0.9900
3:48295069:ACTCA:A	donor_loss	0.9900
3:48295074:CCCG:C	donor_gain	0.9900
3:48295234:C:T	acceptor_gain	0.9900
3:48295237:T:A	acceptor_loss	0.9900
3:48298422:CTTA:C	donor_loss	0.9900
3:48298423:TTA:T	donor_loss	0.9900
3:48298424:TACC:T	donor_loss	0.9900

AlphaMissense

1200 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:48295091:G:C	N126K	0.997
3:48295091:G:T	N126K	0.997
3:48295186:A:G	W95R	0.997
3:48295186:A:T	W95R	0.997
3:48298460:C:A	K19N	0.997
3:48298460:C:G	K19N	0.997
3:48295095:C:G	R125P	0.996
3:48296148:G:C	F68L	0.996
3:48296148:G:T	F68L	0.996
3:48296150:A:G	F68L	0.996
3:48294763:G:C	F145L	0.994
3:48294763:G:T	F145L	0.994
3:48294765:A:G	F145L	0.994
3:48295096:G:T	R125S	0.994
3:48295171:C:G	G100R	0.994
3:48295171:C:T	G100R	0.994
3:48295181:C:A	R96S	0.994
3:48295181:C:G	R96S	0.994
3:48295212:A:T	L86H	0.994
3:48298462:T:C	K19E	0.994
3:48295082:A:C	H129Q	0.993
3:48295082:A:T	H129Q	0.993
3:48295182:C:G	R96T	0.993
3:48296127:G:C	F75L	0.993
3:48296127:G:T	F75L	0.993
3:48296129:A:G	F75L	0.993
3:48295084:G:C	H129D	0.992
3:48295104:G:A	T122I	0.992
3:48295110:C:T	G120D	0.992
3:48295170:C:T	G100E	0.992

dbSNP variants (sampled 300 via entrez): RS1000337521 (3:48297263 T>A), RS1000455184 (3:48296811 G>A,C), RS1000669753 (3:48299005 T>G), RS1000701622 (3:48303317 A>C), RS1000716580 (3:48291977 G>A,T), RS1000822576 (3:48298737 T>A,C), RS1000832479 (3:48292281 T>C), RS1001291746 (3:48293192 C>A), RS1001575934 (3:48293666 T>C), RS1001905738 (3:48291861 G>A), RS1002005156 (3:48298200 C>T), RS1002057294 (3:48297936 C>T), RS1002350361 (3:48300833 G>A), RS1002458414 (3:48300524 T>A,C), RS1002550271 (3:48303053 A>C,G)

Disease associations

OMIM: gene MIM:608294 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST010698_80	Subcortical volume (min-P)	3.000000e-24
GCST010699_110	Brain morphology (min-P)	4.000000e-08
GCST010701_52	Cortical surface area (MOSTest)	1.000000e-16
GCST010702_36	Subcortical volume (MOSTest)	1.000000e-10
GCST010703_262	Brain morphology (MOSTest)	2.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
di-n-butylphosphoric acid	affects expression	1
1,4-phenylenebis(methylene)selenocyanate	affects expression	1
(+)-JQ1 compound	decreases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aspirin	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Hydrogen Peroxide	affects expression	1
Menthol	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Selenomethionine	affects expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1
Copper Sulfate	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3CI	Abcam HEK293T NME6 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.